Searchable abstracts of presentations at key conferences in endocrinology

ea0015oc2 | Young Endocrinologist prize session | SFEBES2008

The ghrelin-cannabinoid axis: a novel pathway in the regulation of appetite and metabolism

Amin Faisal , Kola Blerina , Christ-Crain Mirjam , Lolli Francesca , Wittmann Gabor , Harvey-White Judith , Kunos George , Grossman Ashley B , Fekete Csaba , Korbonits Marta

We have previously shown that the orexigenic and peripheral adipogenic effects of ghrelin are mediated by its effect on the metabolic enzyme AMPK. As the cannabinoid (CB1)-antagonist rimonabant inhibits the orexigenic effect of ghrelin, we suggest that there is an interaction between cannabinoids and ghrelin.To study the involvement of CB1 in the effects of ghrelin, wild-type (WT) and CB1-knockout mice were treated with ghrelin and rimonabant.<p clas...

ea0016oc1.6 | Neuroendocrinology and pituitary | ECE2008

The metabolic effects of ghrelin and glucocorticoids are mediated by AMP-activated protein kinase (AMPK) and endogenous cannabinoids

Kola Blerina , Christ-Crain Mirjam , Farkas Imre , Wittmann Gabor , Lolli Francesca , Seboek Dalma , Harvey-White Judith , Kunos George , Muller Beat , Arnaldi Giorgio , Giacchetti Gilberta , Boscaro Marco , Grossman Ashley B , Fekete Csaba , Korbonits Marta

Ghrelin, cannabinoids and glucocorticoids have all orexigenic and widespread metabolic effects. AMPK is a major controller of many metabolic processes. We have studied the effects of ghrelin and glucocorticoids and their interaction with endocannabinoids using cannabinoid-receptor-1 (CB1) knock-out mice and CB1 antagonist-treated mice, and using tissue samples from patients with CushingÂ’s syndrome and from a rodent model of CushingÂ’s syndrome. AMPK activity and downs...